![img](/in/products/glyxambi/sites/default/files/2023-04/bg%402x.jpg)
Powerful Efficacy.
Ensured Safety.
Convenient Dosing.
Other benefits vs. Glimepiride
Empagliflozin demonstrates lower risk of hypoglycaemia¹
![16-9-copy-3@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-3%402x_5.png)
![16-9-copy-3@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-3%402x_5.png)
FDC: Fixed-dose combination, HbAlc: Glycated haemoglobin, SE: Standard error, EMPA: Empagliflozin, LINA: Linagliptin, Cl: Confidence interval.
References:
Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
Gallwitz B, et al. Lancet. 2012;380:475-83.
Linagliptin demonstrates lower risk of hypoglycaemia1
![16-9-copy-4@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-4%402x.png)
![16-9-copy-4@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-4%402x.png)
FDC: Fixed-dose combination, HbAlc: Glycated haemoglobin, SE: Standard error, EMPA: Empagliflozin,
LINA: Linagliptin, Cl: Confidence interval.
References:
Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
Gallwitz B, et al. Lancet. 2012;380:475-83.
Greater weight loss benefit of Empagliflozin vs. Glimepiride1*
![16-9-copy-3@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-3%402x_6.png)
![16-9-copy-3@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-3%402x_6.png)
*Glyxambi® is not indicated for weight reduction.
FDC: Fixed-dose combination, Cl: Confidence interval, SE: Standard error, BP: Blood pressure.
References:
Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
Gallwitz B, et al. Lancet. 2012;380:475-83.
Greater weight loss benefit of Linagliptin vs. Glimepiride1*
![16-9-copy-4@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-4%402x_0.png)
![16-9-copy-4@2x](/in/products/glyxambi/sites/default/files/2023-04/16-9-copy-4%402x_0.png)
*Glyxambi® is not indicated for weight reduction.
FDC: Fixed-dose combination, Cl: Confidence interval, SE: Standard error, BP: Blood pressure.
References:
Salsali A, et al. Diabetes Obes Metab. 2018; 20(12):2768-2777.
Gallwitz B, et al. Lancet. 2012;380:475-83.